Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

GCC Idiopathic Pulmonary Fibrosis Treatment Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Market Overview:

The GCC idiopathic pulmonary fibrosis treatment market is expected to exhibit a CAGR of 11.60% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Idiopathic pulmonary fibrosis (IPF) refers to a chronic lung disease that affects the tissue surrounding the air sacs. This condition causes the buildup of scar tissues in the alveoli, which hinders its oxygen-carrying functionalities. The common symptoms of IPF include breathing difficulties, dry cough, fatigue, loss of appetite, and swollen limbs. IPF is diagnosed via various chest imaging evaluations, like antibody tests, lung biopsies, and pulmonary function tests. Its treatment plan includes anti-fibrotic drugs and other supportive treatment options, such as oxygen therapy and palliative care.

GCC Idiopathic Pulmonary Fibrosis Treatment Market Trends:

The rising prevalence of fibrotic diseases, especially among the geriatric population, represents the key factor driving the GCC IPF treatment market growth. Improving living standards and the increasing consumption of nicotine-based products are further catalyzing the market growth. Moreover, rapid advancements in the IPF diagnostic techniques are propelling the market growth. In line with this, leading players are undertaking several initiatives to create awareness regarding the disease. For instance, in 2020, Boehringer Ingelheim, a Germany-based pharmaceutical company, launched a website customized in the Arabic language to conveniently cater to the increasing demand for effective management strategies of IPF. Such measures are positively influencing the GCC market growth for IPF treatment.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the GCC idiopathic pulmonary fibrosis treatment market, along with forecasts at the country and regional level from 2022-2027. Our report has categorized the market based on drug class and end user.

Breakup by Drug Class:

  • MAPK Inhibitors
  • Tyrosine Inhibitors
  • Autotaxin Inhibitors
     

Breakup by End User:

  • Hospitals
  • Long-term Care Facilities
  • Others
     

Breakup by Country:

  • Saudi Arabia
  • UAE
  • Qatar
  • Oman
  • Kuwait
  • Bahrain
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Report Coverage:

Report Features Details
Base Year of the Analysis 2021
    Historical Period 2016-2021
Forecast Period 2022-2027
Units US$ Million
Segment Coverage Drug Class, End User, Country
Region Covered Saudi Arabia, UAE, Qatar, Oman, Kuwait, Bahrain
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2699
Five User License: US$ 3699
Corporate License: US$ 4699
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Key Questions Answered in This Report:

  • How has the GCC idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the GCC idiopathic pulmonary fibrosis treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the GCC idiopathic pulmonary fibrosis treatment market and who are the key players?
  • What is the degree of competition in the industry?

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    GCC Idiopathic Pulmonary Fibrosis Treatment Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Drug Class
    6.1    MAPK Inhibitors
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Tyrosine Inhibitors
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    Autotaxin Inhibitors
        6.3.1 Market Trends
        6.3.2 Market Forecast
7    Market Breakup by End User
    7.1    Hospitals
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Long-term Care Facilities
        7.2.1 Market Trends
        7.2.2 Market Forecast
    7.3    Others
        7.3.1 Market Trends
        7.3.2 Market Forecast
8    Market Breakup by Country
    8.1    Saudi Arabia
        8.1.1 Market Trends
        8.1.2 Market Breakup by Drug Class
        8.1.3 Market Breakup by End User
        8.1.4 Market Forecast
    8.2    UAE
        8.2.1 Market Trends
        8.2.2 Market Breakup by Drug Class
        8.2.3 Market Breakup by End User
        8.2.4 Market Forecast
    8.3    Qatar
        8.3.1 Market Trends
        8.3.2 Market Breakup by Drug Class
        8.3.3 Market Breakup by End User
        8.3.4 Market Forecast
    8.4    Oman
        8.4.1 Market Trends
        8.4.2 Market Breakup by Drug Class
        8.4.3 Market Breakup by End User
        8.4.4 Market Forecast
    8.5    Kuwait
        8.5.1 Market Trends
        8.5.2 Market Forecast
    8.6    Bahrain
        8.6.1 Market Trends
        8.6.2 Market Forecast
9    SWOT Analysis
    9.1    Overview
    9.2    Strengths
    9.3    Weaknesses
    9.4    Opportunities
    9.5    Threats
10    Value Chain Analysis
11    Porters Five Forces Analysis

    11.1    Overview
    11.2    Bargaining Power of Buyers
    11.3    Bargaining Power of Suppliers
    11.4    Degree of Competition
    11.5    Threat of New Entrants
    11.6    Threat of Substitutes
12    Price Analysis
13    Competitive Landscape

    13.1    Market Structure
    13.2    Key Players
    13.3    Profiles of Key Players

List of Figures

Figure 1: GCC: Idiopathic Pulmonary Fibrosis Treatment Market: Major Drivers and Challenges
Figure 2: GCC: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016-2021
Figure 3: GCC: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2021
Figure 4: GCC: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2021
Figure 5: GCC: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Country (in %), 2021
Figure 6: GCC: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 7: GCC: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 8: GCC: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 9: GCC: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: GCC: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: GCC: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: GCC: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: GCC: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: GCC: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: GCC: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: GCC: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: GCC: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: GCC: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2021
Figure 21: Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2021
Figure 22: Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: UAE: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: UAE: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2021
Figure 25: UAE: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2021
Figure 26: UAE: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Qatar: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: Qatar: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2021
Figure 29: Qatar: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2021
Figure 30: Qatar: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: Oman: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: Oman: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2021
Figure 33: Oman: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2021
Figure 34: Oman: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Kuwait: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Kuwait: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: Bahrain: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: Bahrain: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: GCC: Idiopathic Pulmonary Fibrosis Treatment Industry: SWOT Analysis
Figure 40: GCC: Idiopathic Pulmonary Fibrosis Treatment Industry: Value Chain Analysis
Figure 41: GCC: Idiopathic Pulmonary Fibrosis Treatment Industry: Porter’s Five Forces Analysis

List of Tables

Table 1: GCC: Idiopathic Pulmonary Fibrosis Treatment Market: Key Industry Highlights, 2021 and 2027
Table 2: GCC: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Drug Class (in Million US$), 2022-2027
Table 3: GCC: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by End User (in Million US$), 2022-2027
Table 4: GCC: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Country (in Million US$), 2022-2027
Table 5: GCC: Idiopathic Pulmonary Fibrosis Treatment Market: Competitive Structure
Table 6: GCC: Idiopathic Pulmonary Fibrosis Treatment Market: Key Players


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2699

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links